Joint chairsAngelyn Bethel
Chief adviser:Rury Holman
Chief investigator:Simon Griffin
Sponsor:Cambridge University Hospitals NHS Foundation Trust
University of Cambridge
Funder:NIHR Health Technology Assessment (HTA) programme
The Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT) is a multi-centre, randomised, double-blind, parallel-group, pragmatic, primary prevention trial comparing the effect of slow-release metformin with placebo on a macrovascular composite outcome in people in primary care with non-diabetic hyperglycaemia and at high cardiovascular risk. Participants will be allocated randomly to treatment with either metformin XR or placebo, and will be followed for 5-7 years.
GLINT is run jointly by the University of Cambridge MRC Epidemiology Unit, the University of Oxford Diabetes Trials Unit (DTU) and the Leicester Diabetes Centre. The joint trial Sponsors are the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The feasibility phase of GLINT is funded by the NIHR Health Technology Assessment (HTA) programme.
The GLINT feasibility phase of 500 individuals commenced in 2015. If successful, this will lead into the main trial and recruitment will be expanded to approximately 12,900 UK participants.
DTU Deputy Director Angelyn Bethel is replacing Prof. Rury Holman as Joint Chair of GLINT with Prof. Nick Wareham. Prof. Holman will continue to support the study in the role of Chief Adviser.
The first GLINT participant was enrolled on 10th March 2015. The feasibility phase of GLINT is planned to continue until November 2015, recruiting 500 participants in total.